| A randomized trial of convalescent plasma in Covid-19 severe pneumonia VA Simonovich, LD Burgos Pratx, P Scibona, MV Beruto, MG Vallone, ... New England Journal of Medicine 384 (7), 619-629, 2021 | 1061 | 2021 |
| Major clinical outcomes in antiretroviral therapy (ART)–naive participants and in those not receiving ART at baseline in the SMART study Strategies for Management of Antiretroviral Therapy (SMART) Study Group The Journal of infectious diseases 197 (8), 1133-1144, 2008 | 580 | 2008 |
| Cabotegravir for HIV prevention in cisgender men and transgender women RJ Landovitz, D Donnell, ME Clement, B Hanscom, L Cottle, L Coelho, ... New England Journal of Medicine 385 (7), 595-608, 2021 | 564 | 2021 |
| Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy JK Rockstroh, A Mocroft, V Soriano, C Tural, MH Losso, A Horban, O Kirk, ... The Journal of infectious diseases 192 (6), 992-1002, 2005 | 551 | 2005 |
| Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study N Friis-Møller, R Thiebaut, P Reiss, R Weber, A D'Arminio Monforte, ... European journal of cardiovascular prevention & rehabilitation 17 (5), 491-501, 2010 | 453 | 2010 |
| Interleukin-2 therapy in patients with HIV infection INSIGHT–ESPRIT Study Group and SILCAAT Scientific Committee New England Journal of Medicine 361 (16), 1548-1559, 2009 | 433 | 2009 |
| Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2 … P Cahn, JS Madero, JR Arribas, A Antinori, R Ortiz, AE Clarke, CC Hung, ... The Lancet 393 (10167), 143-155, 2019 | 420 | 2019 |
| Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study A Mocroft, AN Phillips, J Gatell, B Ledergerber, M Fisher, N Clumeck, ... The Lancet 370 (9585), 407-413, 2007 | 330 | 2007 |
| Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses H Pan, R Peto, AMH Restrepo, MP Preziosi, V Sathiyamoorthy, QA Karim, ... The Lancet 399 (10339), 1941-1953, 2022 | 270 | 2022 |
| Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study JP Viard, JC Souberbielle, O Kirk, J Reekie, B Knysz, M Losso, J Gatell, ... Aids 25 (10), 1305-1315, 2011 | 246 | 2011 |
| Sequence Analysis of In Vivo Defective Interfering-Like RNA of Influenza A H1N1 Pandemic Virus K Saira, X Lin, JV DePasse, R Halpin, A Twaddle, T Stockwell, B Angus, ... Journal of virology 87 (14), 8064-8074, 2013 | 182 | 2013 |
| Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial SMART Study Group* Annals of internal medicine 149 (5), 289-299, 2008 | 165 | 2008 |
| Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has … M Aboud, R Kaplan, J Lombaard, F Zhang, JA Hidalgo, E Mamedova, ... The Lancet infectious diseases 19 (3), 253-264, 2019 | 162 | 2019 |
| Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial RT Davey, E Fernández-Cruz, N Markowitz, S Pett, AG Babiker, ... The Lancet Respiratory Medicine 7 (11), 951-963, 2019 | 129 | 2019 |
| Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study DN Podlekareva, AMW Efsen, A Schultze, FA Post, AM Skrahina, ... The lancet HIV 3 (3), e120-e131, 2016 | 113 | 2016 |
| Infectious Disease Morbidity Among Young HIV-1–Exposed But Uninfected Infants in Latin American and Caribbean Countries: The National Institute of Child Health and Human … MM Mussi-Pinhata, L Freimanis, AY Yamamoto, J Korelitz, JA Pinto, ... Pediatrics 119 (3), e694-e704, 2007 | 111 | 2007 |
| When should antiretroviral therapy for HIV be started? AN Phillips, BG Gazzard, N Clumeck, MH Losso, JD Lundgren Bmj 334 (7584), 76-78, 2007 | 106 | 2007 |
| Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy FV Leth, BS Kappelhoff, D Johnson, MH Losso, A Boron-Kaczmarska, ... AIDS Research & Human Retroviruses 22 (3), 232-239, 2006 | 99 | 2006 |
| Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised … JH Beigel, Y Bao, J Beeler, W Manosuthi, A Slandzicki, SM Dar, J Panuto, ... The Lancet Infectious Diseases 17 (12), 1255-1265, 2017 | 95 | 2017 |
| A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial MaxCmin2 trial group, UB Dragsted, J Gerstoft, M Youle, Z Fox, M Losso, ... Antiviral therapy 10 (6), 735-743, 2005 | 95 | 2005 |